TRITERPENOID THERAPEUTICS INC
Triterpenoid small-molecule therapeutics for glioblastoma treatment
- Sector
- Biotech
- Headquarters
- Braintree, MA
- Total capital
- $2.3M
- Federal grants
- $1.9M
- 5 awards · 2019–2020
- Rank in peer group#322 of 326
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $400K
- 1 award · Health and Human S
- Rank in Biotech#243 of 4373
- Granted patents
- 3
- 12 pending · first 2025
- Rank in peer group#45 of 326
Capital timeline
Latest events
- Federal contractHealth and Human S · Topic 430: A New Small Molecule Senotherapeutic For The Chemoprevention Of Therapy-related Cognitive Aging$400K
- Federal grantHealth and Human S · Phase I · Development of the New Synthetic Triterpenoid CDDO-2P-Im for Chemoprevention of the ARDS of COVID-19$250K
- Federal grantHealth and Human S · Phase I · Development of the New Synthetic Triterpenoid CDDO-2P-IM (TTX01) for Glioblastoma$400K
- Federal grantHealth and Human S · Phase I · Development of the New Synthetic Triterpenoid CDDO-2P-IM (TTX01) for Glioblastoma$400K
- Federal grantHealth and Human S · Phase I · Development of the New Synthetic Triterpenoid CDDO-2P-Im for Chemoprevention of the ARDS of COVID-19$550K
- Federal grantHealth and Human S · Phase I · Development of the New Synthetic Triterpenoid CDDO-2P-IM (TTX01) for Multiple Myeloma$300K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#45 · top 14%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 3 granted of 15- GrantedAnalogs Of CDDO-2P-IM And CDDO-3P-IMUSPTOUS 12,649,763
- GrantedMethods And Compositions For Irreversible Enzyme InhibitionUSPTOUS 12,551,562
- PendingMethods And Compositions For Inhibiting The NLRP3 Inflammasome And/or Lon ProteaseUSPTOApplication 19195035
Show all 15 patent records
- Analogs Of CDDO-2P-IM And CDDO-3P-IMJun 9, 2026 · US 12,649,763Granted
- Methods And Compositions For Irreversible Enzyme InhibitionFeb 17, 2026 · US 12,551,562Granted
- Methods And Compositions For Inhibiting The NLRP3 Inflammasome And/or Lon ProteaseAug 14, 2025 · Application 19195035Pending
- Methods And Compositions For Inhibiting The NLRP3 Inflammasome And/or Lon ProteaseJul 29, 2025 · US 12,370,202Granted
- Analogs Of CDDO-3P-IMApplication 63077869Pending
- Methods And Compositions For Irreversible Enzyme InhibitionApplication PCTUS2020027588Pending
- Methods And Compositions For Treating And Preventing Viral InfectionApplication 63003534Pending
- Methods And Compositions For Inhibiting The NLRP3 Inflammasome And/or Lon ProteaseApplication PCTUS2020017956Pending
- Methods And Compositions For Inhibiting The NLRP3 Inflammasome And/or Lon ProteaseApplication 62947928Pending
- Methods And Compositions For Inhibiting The NLRP3 Inflammasome And/or Lon ProteaseApplication 62913966Pending
- Methods And Compositions For Irreversible Enzyme InhibitionApplication 62832543Pending
- Methods And Compositions For Inhibiting The NLRP3 InflammasomeApplication 62806256Pending
- Analogs Of CDDO-2P-IM And CDDO-3P-IMApplication PCTUS2021050183Pending
- Methods And Compositions For Treating And Preventing Viral InfectionApplication PCTUS2021024910Pending
- Analogs Of CDDO-2P-IMApplication 63077873Pending
Related companies, and why
- ExelixisSimilar federal contract value in Biotech · $401K in contracts
- Stemgent, Inc.Similar federal contract value in Biotech · $400K in contracts
- RIPTIDE THERAPEUTICS LLCSimilar federal contract value in Biotech · $400K in contracts
- ENRICH BIOSYSTEMS INCSimilar federal contract value in Biotech · $400K in contracts
- CYTOBIOSCIENCE INCSimilar federal contract value in Biotech · $387K in contracts
- SIGNABLOK, INC.Similar federal contract value in Biotech · $370K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .